Wire · regulatory
Drug that treats nonobstructive HCM gains FDA Fast Track designation
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 31 July 2026 · Fusion42 review
The FDA has granted Fast Track designation to Haya Therapeutics' HTX-001, an investigational RNA-guided therapy for nonobstructive hypertrophic cardiomyopathy (nHCM), a condition with no current targeted treatments. This status may accelerate the drug's development and review process in the United States.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new path to faster FDA engagement if you develop therapies for rare cardiomyopathies. This opens doors for RNA-targeting treatments to access expedited clinical review in serious unmet markets.
◆ Coverage
1 source · 31 Jul 2026
◆ Related on Wire
◆ Topics
BiotechFDAfast-trackcardiologylncRNAdrug-development